Description: |
This is an open-label, single-arm, dose-escalation Phase I study to determine the maximum tolerated dose (MTD) of G-202 when administered once daily for 3 consecutive days of a 28-day cycle in patients with advanced solid tumors. G-202 will be administered by intravenous infusion over 1 hour on Days 1, 2 and 3 of each 28-day cycle. |
Link: |
An Open-Label, Single Arm, Dose-Escalation Phase 1 Study of G202 |
Site: |
Johns Hopkins Hospital |
Principal Investigator: |
Michael Carducci, MD |